Despite several developed treatment protocols used for treatment of patient with precursor B-cell leukemia/lymphoma, many of these patients relapse. Most of these patients relapse from clinically inapparent minimal residual disease (MRD), which refers to the presence of clonal cells in BM after treatment in a level below the morphological detection. The ability to predict who will relapse while still in a minimal disease state has important clinical implications. A reliable technique for MRD detection should be specific, sensitive, reproducible and quantitative. Currently, PCR analysis of Ag...